| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | WNT7A |
| Uniprot No | O00755 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-349aa |
| 氨基酸序列 | LGASIICNKI PGLAPRQRAI CQSRPDAIIV IGEGSQMGLD ECQFQFRNGR WNCSALGERT VFGKELKVGS REAAFTYAII AAGVAHAITA ACTQGNLSDC GCDKEKQGQY HRDEGWKWGG CSADIRYGIG FAKVFVDARE IKQNARTLMN LHNNEAGRKI LEENMKLECK CHGVSGSCTT KTCWTTLPQF RELGYVLKDK YNEAVHVEPV RASRNKRPTF LKIKKPLSYR KPMDTDLVYI EKSPNYCEED PVTGSVGTQG RACNKTAPQA SGCDLMCCGR GYNTHQYARV WQCNCKFHWC CYVKCNTCSE RTEMYTCK |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于WNT7A重组蛋白的3篇参考文献示例(文献为虚构，仅供参考格式)：
1. **《WNT7A重组蛋白通过经典信号通路促进神经轴突再生》**
- 作者：Smith J. et al.
- 摘要：本研究利用HEK293细胞表达并纯化功能性WNT7A重组蛋白，发现其通过激活经典Wnt/β-catenin通路显著增强体外培养的神经元轴突延伸，为神经损伤修复提供了潜在治疗策略。
2. **《高效生产可溶性WNT7A重组蛋白的昆虫细胞表达系统优化》**
- 作者：Zhang Y. et al.
- 摘要：通过杆状病毒-昆虫细胞表达系统优化WNT7A重组蛋白的分泌表达，解决了传统哺乳动物系统中蛋白聚集问题，获得高活性产物，并验证其在体外促间充质干细胞成骨分化的功能。
3. **《WNT7A重组蛋白抑制非小细胞肺癌侵袭的机制研究》**
- 作者：Lee H. et al.
- 摘要：研究发现外源性WNT7A重组蛋白能通过非经典Wnt/Ca²⁺通路下调EMT标记物表达，抑制肺癌细胞迁移和侵袭，提示其作为肿瘤转移干预靶点的潜力。
4. **《WNT7A重组蛋白在软骨发育中的时空特异性作用》**
- 作者：Brown K. et al.
- 摘要：利用重组WNT7A蛋白处理小鼠肢芽模型，揭示其通过调控Sox9表达促进软骨前体细胞增殖与分化，为骨骼发育异常疾病研究提供了分子基础。
(注：以上文献为模拟示例，实际研究中请通过学术数据库检索真实文献。)
WNT7A is a secreted glycoprotein belonging to the Wnt family, which plays pivotal roles in embryonic development, tissue homeostasis, and disease. As a key ligand in Wnt signaling pathways, it primarily activates the β-catenin-dependent canonical pathway and modulates non-canonical pathways, influencing cell proliferation, differentiation, and polarity. Recombinant WNT7A protein is engineered to mimic the native protein’s biological activity, typically produced using mammalian expression systems (e.g., HEK293 or CHO cells) to ensure proper post-translational modifications, such as glycosylation and palmitoylation, critical for receptor binding and signaling efficacy.
Research on recombinant WNT7A has highlighted its involvement in diverse processes. In development, it regulates limb patterning, neural tube closure, and organogenesis. Dysregulation of WNT7A is linked to pathologies, including pulmonary fibrosis, skeletal malformations, and cancers. For instance, WNT7A loss-of-function mutations are associated with Müllerian duct anomalies, while its overexpression in certain tumors may drive metastasis. These findings underscore its dual role as both a developmental regulator and a potential therapeutic target.
The recombinant protein is widely used in vitro and in vivo to study signaling mechanisms, screen modulators, or rescue phenotypes in disease models. Challenges in handling WNT7A stem from its hydrophobic nature (due to lipid modifications) and low solubility, often requiring carrier proteins or specialized buffers. Quality control assays, such as ELISA, Western blot, and functional cell-based assays (e.g., TOPFlash reporter), ensure batch consistency. Recent advances in protein engineering aim to enhance stability and delivery efficiency, broadening its applications in regenerative medicine and drug discovery.
×
